Bictegravir-Based Antiretroviral Therapy-Associated Accelerated Hyperglycemia and Diabetes Mellitus
Nathanial S Nolan, Samantha E. Adamson, Dominic N. Reeds, Jane A. O’Halloran
Abstract
Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) is first line for treatment of people with human immunodeficiency virus (PWH). Emerging data suggest the possibility of adverse metabolic effects of these medications. We describe 3 cases in which PWH developed hyperglycemia and ketoacidosis within months of being switched to bictegravir-based ART.
Topics & Concepts
MedicineAntiretroviral therapyAdverse effectDiabetes mellitusHuman immunodeficiency virus (HIV)DolutegravirDiabetic ketoacidosisIntegrase inhibitorVirologyIntensive care medicineInternal medicineViral loadEndocrinologyHIV-related health complications and treatmentsHIV/AIDS drug development and treatmentHIV Research and Treatment